News
Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH
With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease
On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis),
Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.
(CNN) - Patients in the United States can now get the popular diabetes and weight loss drug Ozempic for half the price. Novo ...
The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a [form of liver disease]( ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback